A study by Ma et al. [147] demonstrated that CAR-T cells that targeted the PSMA demonstrated a potent PCa-killing impact, and second-generation CAR-T cells outperformed the first generation, presenting a potential method for clinical immune-targeted therapy for CRPC. This evidence concerns the gene FOLH1 and posterior cortical atrophy.